Life Insurance with Lupus | SLE Life Insurance | High Risk

Lupus (systemic lupus erythematosus, or SLE) is an autoimmune condition with highly variable underwriting outcomes. Mild lupus limited to skin and joints with no major organ involvement and infrequent flares may qualify for coverage at a table rating at select carriers. Lupus with kidney involvement (lupus nephritis), CNS involvement, or frequent hospitalizations typically results in decline at standard carriers. Organ involvement, flare frequency, medication regimen, and damage index are the variables that drive everything.

What Underwriters Evaluate for Lupus

Organ Involvement — The most critical factor. Lupus limited to skin and joints (cutaneous, musculoskeletal) is viewed most favorably. Kidney involvement (lupus nephritis), CNS manifestations, cardiac involvement (pericarditis, endocarditis), or pulmonary involvement significantly worsens the underwriting outcome.

Flare Frequency and Hospitalizations — Carriers look at flare frequency and severity over the past 2–5 years. Infrequent, mild flares managed without hospitalization are viewed most favorably. Frequent flares or hospitalizations within the past 12–24 months trigger postponement or decline.

Medications — Hydroxychloroquine (Plaquenil) alone or with NSAIDs is the most favorable medication profile. High-dose corticosteroids or immunosuppressants (mycophenolate, azathioprine, cyclophosphamide) signal more severe disease and typically result in higher table ratings.

SLICC Damage Index — Accumulated organ damage from lupus over time is a key metric. Low or zero damage index with minimal scarring or organ changes is viewed most favorably. Progressive organ damage significantly restricts options.

Kidney Function (if nephritis present) — If lupus nephritis is present, eGFR and proteinuria levels become critical metrics. Preserved kidney function with well-controlled nephritis may still be insurable at some carriers; significantly impaired function typically results in decline.

Lupus Profile: General Underwriting Outlook

Lupus Profile	Typical Rating	Best Achievable	Notes
Skin/joint only, infrequent flares, hydroxychloroquine	Table 4–6	Table 4 at select carriers	Most favorable presentation; minimal organ involvement
Mild multi-system, controlled, low-dose steroids	Table 6–8	Table 6	Limited options; carrier selection critical
Lupus nephritis, stable kidney function	Table 8–10 or decline	Very limited options	Kidney involvement substantially restricts the field
CNS involvement, major organ damage, or frequent hospitalization	Decline	Simplified or guaranteed issue	Standard coverage typically not available

Guidelines current as of 2025–2026. Verify with us before applying.

Situations That Typically Result in Decline

CNS Lupus (Neuropsychiatric SLE) — Central nervous system involvement — including seizures, psychosis, or cognitive impairment attributed to lupus — results in decline at most standard carriers.

Significant Renal Impairment — Lupus nephritis with significantly impaired kidney function (eGFR below 45) results in decline at virtually all standard carriers. Preserved kidney function with well-controlled nephritis has very limited but not zero options.

Antiphospholipid Syndrome (APS) — Lupus combined with APS, particularly with a history of clotting events or stroke, results in decline or very restricted options at standard carriers.

What You Can Do to Improve Your Outcome

Apply during a period of documented disease stability. A 12–24 month period without flares, hospitalizations, or medication escalation is the most important factor in improving your outcome. Timing your application to coincide with stability maximizes your chances.

Minimize steroid use before applying. If you are on chronic corticosteroids, working with your rheumatologist to taper to the lowest effective dose before applying can meaningfully improve your underwriting profile.

Work with a broker who knows lupus underwriting. Carrier selection is critical for lupus cases. Applying to the wrong carrier with lupus history means a decline that affects your MIB record. We informally shop your case before any application is submitted.

Have Lupus? Let’s Find Your Coverage Options.

Lupus underwriting is highly carrier-dependent. We match your specific disease profile to the carriers most likely to offer coverage before any formal application is submitted.

Call 1-888-972-0024

Browse All High-Risk Conditions

Understanding Your Rating: Life Insurance Risk Classifications | Table Ratings Explained (B–J) | Flat Extra Ratings

Authoritative Resources: Life insurance underwriting practices are regulated by the NAIC. Insurers may check your health history through the MIB Group — you can request your free annual MIB report at mib.com.

Frequently Asked Questions

Can I get life insurance with lupus?

Yes. Lupus (SLE) is insurable in many cases, particularly when limited to skin and joint involvement with infrequent flares and no major organ damage. Mild lupus managed with hydroxychloroquine and without hospitalizations can qualify for table-rated coverage at select carriers. Lupus with kidney involvement, CNS manifestations, or frequent hospitalizations significantly restricts options.

Does lupus nephritis prevent me from getting life insurance?

Lupus nephritis makes underwriting significantly more challenging. Well-controlled nephritis with preserved kidney function (eGFR above 60) and normal or near-normal labs may still be insurable at select carriers, typically at Table 8 to Table 10 or higher. Significantly impaired kidney function from nephritis typically results in decline at standard fully underwritten carriers.

How does my lupus medication affect underwriting?

The medication profile is a direct signal of disease severity. Hydroxychloroquine (Plaquenil) alone or with NSAIDs is the most favorable profile. Biologics or immunosuppressants (mycophenolate, azathioprine) signal more severe disease and typically result in higher table ratings. Chronic high-dose corticosteroids are the most negative medication signal, suggesting poorly controlled disease.

What is the most important thing I can do to improve my lupus underwriting outcome?

Apply during a documented period of disease stability — ideally after 12 to 24 months without flares, hospitalizations, or medication escalation. The stable period is the single most influential factor in improving your outcome. If you are on chronic corticosteroids, working with your rheumatologist to taper to the lowest effective dose before applying can also meaningfully improve your rating.

Does having antiphospholipid syndrome (APS) with lupus affect my coverage options?

Yes significantly. Lupus combined with antiphospholipid syndrome, particularly with a history of clotting events or stroke, results in decline or very restricted options at standard carriers. The APS-related clotting history is evaluated as a separate risk factor on top of the lupus itself, compounding the underwriting concern substantially.